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Abstract
Heme (Fe2+ protoporphyrin IX) is an essential molecule that has been implicated the potent antimalarial action of
artemisinin and its derivatives, although the source and nature of the heme remain controversial. Artemisinins also exhibit
selective cytotoxicity against cancer cells in vitro and in vivo. We demonstrate that intracellular heme is the physiologically
relevant mediator of the cytotoxic effects of artemisinins. Increasing intracellular heme synthesis through the addition of
aminolevulinic acid, protoporphyrin IX, or transferrin-bound iron increased the cytotoxicity of dihydroartemisinin, while
decreasing heme synthesis through the addition of succinyl acetone decreased its cytotoxic activity. A simple and robust
high throughput assay was developed to screen chemical compounds that were capable of interacting with heme. A natural
products library was screened which identified the compound coralyne, in addition to artemisinin, as a heme interacting
compound with heme synthesis dependent cytotoxic activity. These results indicate that cellular heme may serve a general
target for the development of both anti-parasitic and anti-cancer therapeutics.
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Introduction
Heme (Fe
2+ protporphyrin IX) is a ubiquitous and essential
tetrapyrrole molecule that performs a wide array of fundamental
physiological functions, including oxygen transport, electron
transfer, and transcriptional regulation. Heme is highly redox
active and is potentially toxic in its free form, which is present at
sub-micromolar concentrations in most cells [1]. Heme has been
implicated in the anti-malarial mechanism of artemisinin (ART)
and its derivatives which are toxic to malaria parasites at
nanomolar concentrations [2]. We have recently shown that
redox active heme is the most efficient and kinetically favorable
activator of artemisinin in vitro relative to oxidized ferric heme
(hemin), inorganic ferrous iron, ferric iron, hemoglobin, or
methemoglobin [3] which show only limited reactivity under
certain experimental conditions [3,4,5,6]. Artemisinin molecules
contain an endoperoxide linkage that is required for anti-parasitic
activity. The endoperoxide bond accepts an electron presumably
from heme, which results in drug activation, subsequent bond
breakage, and the formation of an alkoxyl radical in the
artemisinin molecule [7]. Heme-artemisinin adducts have been
identified in malaria-infected mice [8], a strong indication that the
C4 radical of artemisinin is relevant to the antimalarial activity of
artemisinin.
In addition to acting as an anti-malarial agent, artemisinins are
also selectively cytotoxic to cancer cells in vitro, including drug-
and radiation-resistant cancer cell lines [9]. Artemisinins have also
been shown to be effective against cancer in rodent models
[10,11,12] and have begun to be used in human cancer patients
[13,14,15]. Despite the significant efforts to delineate their anti-
malarial mechanism, how artemisinins exert their cytotoxic effects
has only recently begun to be investigated. Artemisinins have been
reported to inhibit tumor lymphangiogenesis by suppression of
vascular endothelial growth factor C in a mouse lung cancer cell
line [16], block estrogen receptor expression in a human breast
cancer cell line [17], and increase calcium levels and activate p38
in a human lung cancer cells [18].
We hypothesized that the initial interaction with heme served as
a common mechanism of activation for artemisinins in exerting
cytotoxic effects against both malaria parasites and cancer cells.
Cancer cells have an increased capacity to synthesize heme [19],
as well increased requirements for iron from increased synthetic
demand due to higher rates of proliferation [20]. Aminolevulinic
acid (ALA), a heme precursor derived from the condensation of
glycine and succinyl-CoA in the mitochondria by the enzyme ALA
synthase which is the rate-limiting step in the heme synthesis
pathway and is feedback inhibited by heme, has been used as a
pharmacological agent to increase heme synthesis to generate
photosensitive heme precursors such as PPIX for photodynamic
therapy in treating cancers [21,22].
We demonstrate that pharmacological inhibition of heme
synthesis decreases the cytotoxicity of artemisinins, while stimu-
lation increases cytotoxicity. We also developed an in vitro high-
throughput heme interaction assay to screen a library of natural
products that identified several compound(s) with reactivity
towards heme that exhibited exquisite molecular specificity. One
compound, coralyne, was highly cytotoxic with dependence upon
heme synthesis. The heme interaction high-throughput screening
assay may serve as a useful tool to identify new compounds against
cancer, malaria, and other parasites. Heme may be an especially
attractive target molecule for the development of a new molecular
class of chemotherapeutic agents.
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Chemicals
Dihydroartemisinin (DHA) and sodium artesunate (ATS) were a
generous gift from Dafra Pharma N.V. (Belgium). All other
chemicals were obtained from Sigma-Aldrich (St. Louis, MO).
Hemin, PPIX, ART, DHA, and ATS and peroxide compounds
were prepared in DMSO (used immediately or stored at 220uC
for later use). Succinyl acetone (SA), ALA and holotransferrin
(HTF) were prepared in 0.1 M phosphate buffer, pH 7.0. Sodium
dithionite solution was freshly prepared for each assay in 80 mM
phosphate buffer, pH 7.0 containing 20% DMSO.
Heme Interaction Assay
The following reagents were added in sequence into standard
clear flat bottom polystyrene 96 well microplate (Costar) wells:
hemin (0.125 mM in DMSO, final 20 uM), chemical compounds
(in DMSO at 40 uM), dithionite (200 mM in 80 mM phosphate
buffer pH 7.0, containing 20% DMSO, final 160 mM). The
molar ratio of compound:heme was 2:1. Parallel wells for each
compound were prepared that did not contain hemin. The plate
was shaken 10 times in the microplate reader before reading at
415 nm using a Spectra MAX250 Microplate Reader (Sunnyvale,
CA, USA). The absorbance of wells without heme was subtracted
from the corresponding wells with hemin for each microplate. The
positive control contained DHA (10:1 to heme) and for the
negative control DHA was omitted.
Natural Product Library Screen
The 720 compound Natural Product Collection library
(Supporting Information S1) from Microsource Discovery
Systems, Inc. (Gaylordsville, CT, U.S.A.) was screened using the
Heme Interaction Assay. Screening aliquots of compounds were
obtained from the 10 mM stock plates by dilution to 1 mM using
DMSO and dispensed into aliquot plates for storage at 280uC. A
final concentration of 40 uM (2:1 molar ratio to heme) was used
for primary screening. To measure the power of the screening
assay, Z-factor analysis [23] was performed (Supporting
Information S1). Data from the primary screen were analyzed
using Z score analysis [24] (Supporting Information S1).
Compounds with a Z-score of $2, or #22, were selected for
follow-up analysis. The secondary screen consisted of repeating the
heme interaction assay using an increased compound concentra-
tion of 200 uM (10:1 molar ratio to heme) and the compounds
with greater than a 10% A415 reduction were selected for further
absorption spectral and cytotoxic analyses.
Cell Culture and cytotoxicity assays
The lymphoblastoid leukemia cell line Molt-4 (ATCC CRL-
1582), the breast cancer cell line MDA-MB-231 (ATCC HTB-26)
and the prostate cancer cell line PC-3 (ATCC CRL-1435) were
obtained from ATCC (Manassas, VA, USA). Molt-4 and MDA-
MB-231 cells were maintained in RPMI-1640 medium, and PC-3
cells were cultured in F-12K medium, supplemented with 10% calf
bovine serum in a humidified incubator with 5% CO2 at 37uC.
Molt-4 cells were seeded at approximately 1610
6/ml followed by
addition of compounds or equal volumes of DMSO and incubated
for 24 hours or 48 hours. Compounds or equal volumes of DMSO
were added to MDA-MB-231 and PC-3 cells at 60% confluence
and incubated for 48 hours. DHA was used at 10 uM, 25 uM, or
40 uM, HTF at 12 uM, SA at 0.5 mM, ALA at 1 mM, and PPIX
at 5 uM. Changes in cell number (proliferation) or cellular ATP
level (cell viability) were analyzed. Live cells were distinguished
from dead cells via Trypan Blue staining and counted using
hemacytometer. The CellTiter-Glo Luminescent Cell Viability
Assay [25] (Promega, WI, USA) was used to measure cellular ATP
levels (Wallac 1420 multilabel counter).
Statistical analysis
Results are presented as mean6s.d. for the indicated number of
experiments. Statistical analyses were performed using one-way
ANOVA and Student’s t-test. A value of P,0.05 was considered
to be statistically significant.
Results
Cytotoxicity of artemisinin depends on heme synthesis
Previous studies have shown that leukemia cells are particularly
sensitive to the artemisinin derivative dihydroartesunate (DHA)
[26]. As an initial cell line to study, we selected MOLT-4 cells
which have also been previously shown to be highly susceptible to
DHA [27,28]. Using this model for DHA cytotoxicity, we
performed a dose response time course study (Figure S1)t o
identify a level of drug that resulted in significant cytotoxicity but
not complete loss of the culture within 24 hours. A DHA
concentration of 25 uM was selected. We then addressed the
potential role of heme as the primary target for the cytotoxicity of
artemisinin towards cancer cells by increasing or decreasing the
rate of heme synthesis, which may be controlled pharmacologi-
cally. MOLT-4 cells were cultured with 25 uM DHA for 24 hours
and cell viability measured via ATP content [25]. At 24 hours, the
ATP level in the DMSO treated control cells increased by 119%
(more than doubled) relative to time=0, which was normalized to
100% in Figure 1A, and the cell number increased by 143%
(normalized to 100% in Figure S2A). The ATP content in the
culture treated with 25 uM DHA (Figure 1A) was only about
35% of the increase in ATP that was measured in control cells
(p,0.05) while the increase in cell number (Figure S2A) was less
than 30% of the increase of control cells (P,0.05). The smaller
decrease in ATP content relative to the decrease in cell number
measured via trypan blue exclusion is consistent with previous
cytotoxicity studies [27]. To block heme synthesis and induce a
relative heme deficiency, exogenous succinyl acetone (SA) was
used to inhibit the enzyme aminolevulinate dehydratase to prevent
the condensation of two molecules of ALA to form porphobilin-
ogen and deplete the remainder of the heme synthetic pathway
[29,30]. The addition of SA by itself at 0.5 mM had no effect on
cell viability or cell number, but essentially completely prevented
cytotoxicity when co-incubated with DHA (Figures 1A and S2A).
These results suggest that on-going heme synthesis may be
essential for DHA cytotoxicity in Molt-4 cells. In addition, cellular
heme levels of early log-growth cells do not appear to be sufficient
to enable DHA cytotoxicity.
We then tested whether increasing heme synthesis could
potentiate the effects of DHA. To increase heme synthesis,
exogenous aminolevulinic acid (ALA) was provided as a heme
synthetic precursor, bypassing the ALA synthetase rate-limiting step
and driving the synthetic pathway [31]. For this experiment,a lower
concentration of DHA (10 uM) was used as a more stringent test for
increased cytotoxicity. In this experiment, at 24 hours, the ATP
level in the DMSO treated control cells increased by 111% relative
to time=0, which was normalized to 100% in Figure 1B, and the
cell number increased by 112% (normalized to 100% in Figure
S2B). The increase in ATP content of the culture exposed to 10 uM
DHA for 24 hours was only 66% of the DMSO control,
(Figure 1B) with a net loss of 4% in cell number from the initial
culture (Figure S2B). Incubation of cells with 1.0 mM ALA by
itself had no effect on the increase in ATP or cell number. However,
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S2B) abrogatedany increase inATP content or cell numberrelative
to control cells and resulted in a further decrease in ATP content
(p,0.05), as well as a further loss in cell number relative to DHA
treated cells (p,0.05). ALA appeared to significantly increase DHA
cytotoxicity. To confirm this, SA was used to counter the effects of
ALA because SA blocks an enzymatic step downstream from where
ALA acts to increase heme synthesis. SA reversed the increased
cytotoxicity of ALA and DHA and resulted in increases in ATP
levels and cell numbers similar to controls (Figures 1B and S2B).
These results suggest that ALA-induced heme synthesis can
potentiate the cytotoxic effects of DHA, which could be blocked
by the addition of SA to inhibit heme synthesis. In order to
determine whether these effects were specific to Molt-4 cells, two
cell lines of disparate tissue origin were analyzed, the breast cancer
cell line MDA-MB-231 and the prostate cancer cell line PC-3. Both
havebeen used inpreviouscytotoxicity studies involvingartemisinin
[32,33]. Because these two cell lines are not as sensitive to the
cytotoxic effects of artemisinin as are Molt-4 cells, a higher
concentration of DHA (40 uM) was used and the incubation period
was extended to 48 hours. DHA decreased cell viability, as
expected, to a similar degree in both cell lines (Figure 2). Cell
viability was further decreased in each of the cell lines by the
addition of ALA, similar to the effect of ALA seen with Molt-4 cells.
SA could then prevent most of the decrease in cell viability from
DHA, although not to as great an extent as with Molt-4 cells. The
mechanism for the lesser effect of SA in these cell lines is not clear,
although the optimum dose of SA needed to maximally suppress
heme synthesis has not been determined.
The modulation of heme synthesis with ALA does not exclude that
other heme precursors may be mediating DHA cytotoxicity. To
provide chemical specificity, protoporphyrin IX (PPIX), the
penultimate molecule in the heme synthetic pathway into which a
ferrous iron is inserted to generate heme, was used to increase heme
synthesis[34]. PPIX at 5 uM had no significant effect on the increase
in ATP content in the culture and caused a slightly decrease (p,0.05)
in the cell number at approximately 84% of the increase in control
cell number (Figures 3A and S3A). However PPIX dramatically
increased the cytotoxicity from DHA, which resulted in 33% loss of
ATP content (p,0.05) relative to control cells and a similar net loss of
cell number (p,0.05) from the initial culture (Figures 3A and S3A).
Co-incubation of PPIX and SA had no effect on the increase in ATP
level or cell number, and when incubated with DHA, did not affect
cytotoxicity (Figures 3A and S3A). This is consistent with PPIX
acting further downstream in the heme synthetic pathway than SA.
Because PPIX does not result in the activation of artemisinin in vitro
Figure 2. Modulation of heme synthesis alters DHA cytotoxic-
ity in MDA-MB-231 and PC-3 cells. (A) Cell viability of MDA-MB-231
cells cultured with DHA, ALA, or SA. ALA further increased the
cytotoxicity of DHA (p,0.001), which was largely reversed by SA
(p,0.001). (B) Cell viability of PC-3 cells cultured with DHA, ALA, or SA.
ALA also further increased the cytotoxicity of DHA (p,0.001), which
was largely reversed by SA (p,0.001), similar to the effects seen with
MDA-MB-231 cells.
doi:10.1371/journal.pone.0007472.g002
Figure 1. Modulation of heme synthesis alters DHA cytotoxic-
ity in MOLT-4 cells. (A) Cellular viability of MOLT-4 cells cultured with
DHA, succinyl acetone (SA), or both for 24 hours was measured using
ATP levels. Values are mean +/2 s.d. for six replicates. SA prevented
DHA’s cytotoxicity (p,0.001). (B) Cell viability of MOLT-4 cells cultured
with DHA, aminolevulinic acid (ALA), and/or SA. ALA further increased
the cytotoxicity of DHA (p,0.001), which was reversed by SA (p,0.001).
doi:10.1371/journal.pone.0007472.g001
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stimulation of heme synthesis.
Another alternative explanation for the role of heme is that it is
merely a means of increasing intracellular iron. To test this
possibility, holotransferrin was added as an additional source of
cellular iron [27]. As shown in Figures 3B and S3B, holotrans-
ferrin alone did not have a significant effect on the increases in ATP
or cell number but dramatically increased the cytotoxic effect of
DHA, an observation previously interpreted as due to the direct
effects of iron [35,36]. However, the newly acquired intracellular
iron could also be used for heme synthesis. The addition of SA
completely negated the effect of holotransferrin (Figures 3B and
S3B), indicating that blocking heme synthesis can block the effect of
iron supplementationvia transferrin. These results suggest that non-
heme iron contributes to the cytotoxicity of artemisinin through its
use for heme synthesis.
Spectrophotometric characterization of the
Heme-Artemisinin interaction
With data supporting a primary role for heme in the mechanism
of artemisinin’s cytotoxicity towards human cancer cells, similar to
its role in activating artemisinin in the killing of malaria parasites,
we hypothesized that heme could serve as a potentially novel
intracellular target for the development of both anti-neoplastic and
anti-parasitic agents. In order to configure a high throughput
assay, we used artemisinin (ART) as a model compound to
characterize the interaction with heme using a simple absorption
spectrum [37]. We have previously shown that artemisinin does
not interact with hemin (oxidized heme) [3]. When hemin (Fe
3+)
was reduced to heme (Fe
2+) by the addition of dithionite, a shift in
the Soret peak absorbance [38] from 389 to 415 nm occurred
(Figure 4). With the addition of artemisinin, the 415 nm Soret
peak decreased and a peak at 476 nm appeared, as previously
observed [37]. As the ratio of artemisinin to heme was increased,
the 415 nm peak was incrementally decreased and was abrogated
at very high drug:heme ratios, while the peak at 476 nm increased
further. The chemical species underlying the peak at 476 nm is not
known but may be due to altered heme porphyrin ring spectral
properties. Deformations of porphyrins are known to result in
significant changes in the chemical and spectroscopic properties of
the porphyrin ring. For example, properties of porphyrin rings can
be modified through non-planar distortions such as altered
oxidation potentials, modified basicity of the inner nitrogen atoms,
and changes in axial ligand binding affinity [39]. Covalent
modification of heme by artemisinin may also be a mechanism
since artemisinin is known to alkylate heme [6].
Sensitivity and specificity of the heme-artemisinin
interaction
The sensitivity and specificity of detection were estimated using
artemisinin, two related artemisinin derivatives, DHA and
artesunate (ATS), as well as amodiaquine, a quinoline anti-
malarial compound. Quinolines mediate their anti-malarial
activity through interruption of hemin polymerization to prevent
the formation of hemozoin that prevents toxicity from heme
derived from ingested red blood cell hemoglobin. No effect on
Soret band absorbance was observed from amodiaquine up to a
ratio of 10:1 with 20 uM heme (Figure 5). However, the assay
was very sensitive for the detection of the artemisinin compounds,
detecting a .20% decrease in A415 absorbance at an artemisinin
drug:heme ratio of 0.4:1 with 20 uM heme (Figure 5).
Figure 3. Effect of protoporphyrin IX and holotransferrin on
DHA cytotoxicity. (A) Cell viability of MOLT-4 cells cultured with DHA,
the heme precursor protoporphyrin IX (PPIX) and/or SA. PPIX increased
DHA cytotoxicity (p,0.001), which could not be reversed by SA,
consistent with PPIX acting later in the heme synthetic pathway than
SA. (B) Cell viability of MOLT-4 cells cultured with DHA, holotransferrin
(HTF), and/or SA. HTF enhanced DHA cytotoxicity (p,0.001), which was
reversed by SA (p,0.001).
doi:10.1371/journal.pone.0007472.g003
Figure 4. Absorbance at 415 nm is a sensitive indicator of the
heme-artemisinin interaction. Absorption spectra of heme with
increasing molar ratios of artemisinin to heme. A decrease in the Soret
415 nm absorbance peak occurs with the appearance of a peak at
476 nm.
doi:10.1371/journal.pone.0007472.g004
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artemisinin was a general mechanism for interaction with heme.
A series of other compounds which possess peroxide groups
including di-tert-amyl peroxide, tert-butyl peroxide, 2-butanone
peroxide, dicumyl peroxide, benzoyl peroxide, lauroyl peroxide,
and 9-a,11-a-di-hydroxy-5,8-epidioxy-5-a,8-a-ergostan-3-b-yl ac-
etate (possesses an endoperoxide group) were not reactive in the
assay at concentrations of 40 uM (Figure S4).
The potential effects of antioxidant compounds on the heme-
artemisinin interaction were also tested. Butylated hydroxytoluene
(BHT) and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic
acid (Trolox) up to 40 uM also had no effect (Figure S5).
Heme Interaction High Throughput Screening (HI HTS)
Assay
Hemin has been used as the target in previous high throughput
screening studies. Approaches involving ultraviolet/visible spec-
trophotometry [40] and high performance liquid chromatogra-
phy/diode array detector/mass spectrometry [41] have been
proposed. While potentially useful as rapid, high throughput
screening methods, such instrumentation may be costly, and are
based upon physico-chemical interactions with hemin. We sought
to develop a simple, robust microplate assay using absorption
spectrometry based upon the interaction of compounds with heme
(not hemin). However, conditions to prevent heme from
spontaneously oxidized and allow for its solubility in aqueous
solution while not interfering with the Soret absorption peak
needed to be empirically determined. Our approach was to
maintain heme in its reduced form using dithionite [42] and to use
sufficient DMSO to maintain heme in its monomeric state [43],
which also eliminated interference of absorbance from dithionite
in overlapping wavelengths with the heme Soret band absorbance.
The decrease in Soret band absorbance at 415 nm that occurs
when heme interacts with artemisinin was selected as a simple
primary readout of a single endpoint assay, rather than using
absorption spectra or focusing on the peak that occurs at 476 nm.
The decrease in the Soret band absorbance will reflect a variety of
alterations of the heme molecule and serves as a general indicator
that a compound is interacting with heme. It is also a major
change in the interaction with artemisinins. The peak observed at
476 nm may be unique to artemisinin. Other compounds may
produce peaks at different wavelengths. Full wavelength spectra
would therefore be useful to detect such new absorption peaks in
secondary screens.
A simple and robust HTS 96 well microplate assay was
developed to monitor heme’s Soret band absorbance at 415 nm as
a single endpoint assay. The assay includes the simple sequential
steps of adding hemin, the chemical compound, and dithionite to
reduce hemin to heme, followed by shaking and reading in a
microplate reader. Parallel wells set up without heme are used to
correct for A415 absorbance by compounds. The assay provides
for a wide detection range, with an absorbance at 415 nm of about
2 absorbance units for 20 uM heme relative to a background
empty well absorbance of about 0.10. Thus, the signal:background
ratio is approximately 20.
Within-plate, plate-to-plate, and day-to-day assay
variation
The variation in the performance of the assay was assessed using
artemisinin. The coefficient of variation (CV) across an entire plate
was 2–4%, whether measured as the variation of the assay without
artemisinin (at about 2 absorbance units), or with a 8 uM:20 uM
artemisinin:heme ratio (at about 1 absorbance unit).
The variation across microplates was similar to the within-plate
variation at ,5% (data not shown). The CV across different days
was less than 8% (Figure S6). A Z-factor analysis [23] yielded a
value of 0.701 on plate measurements performed on 5 consecutive
days, indicating excellent performance. The main reagents used
for the assay, hemin and DMSO, are stable chemicals and are very
inexpensive, another advantage for high throughput screening.
Only the dithionite stock solution was freshly prepared and all
steps in the assay proceed sequentially with no incubations.
Screening of a natural products library
The HI HTS assay was used to conduct an initial feasibility
screen of a library of 720 compounds categorized as natural
products [44]. Each compound was used in the microplate assay at
a final concentration of 40 uM with heme at 20 uM. A primary
screen yielded most compounds with little change in A415
(Figure 6).
Two criteria were used to select compounds for further analysis,
z-score in the primary screen and an arbitrary threshold of .10%
reduction in A415 in the secondary screen. For the primary screen,
Figure 5. Sensitivity and specificity of detection of the heme-
artemisinin interaction. Reduction of A415 peak absorbance was
quantified with increasing drug:heme ratios. Drug compounds include
ART, DHA, and artesunate (ATS), and amodiaquin.
doi:10.1371/journal.pone.0007472.g005
Figure 6. Primary screen of a natural products library for HI
compounds. Percent reduction in A415 absorbance was plotted for
each compound. The molar ratio of compound to heme was 2:1
(40 uM:20 uM).
doi:10.1371/journal.pone.0007472.g006
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subjected to a secondary screen at an increased compound
concentration of 200 uM (10:1 molar ratio to heme). In this
secondary screen, only four compounds passed a threshold of
.10% A415 reduction (Figure S7), including artemisinin (99%
reduction in A415), coralyne (73% reduction in A415), 5a-
cholestan-3b-ol-6-one (35% reduction in A415), and 3-hydroxy-
4(succin-2-yl)-caryolane d-lactone (11% reduction in A415). Arte-
misinin was one of the components of the commercial compound
library. Consistent with the results for the effects of other
antioxidants, nine antioxidant compounds contained in the natural
products library including purpurogallin, silibinin, guaiazulene,
guaiazulenel, chlorogenic acid, 4-acetoxyphenol, pomiferin, epica-
techin, and pyrocatechuic acid, did not exhibit activity in the assay.
The reaction with heme of these four compounds at 200 uM
was further analyzed using absorption spectra from 400 to
500 nm. Lower length wavelengths were not scanned because
dithionite has a broad peak from ,280 to 400 nm that would
interfere. The 400 nm to 500 nm absorption spectrum of the
interaction of heme and artemisinin displayed the characteristic
disappearance of the 415 nm Soret band, as well as the previously
described new peak at ,476 nm (Figure 7). Coralyne also caused
a dramatic decrease of heme Soret band absorbance but did not
generate a new peak in the tested wavelength range. This is
consistent with a significant structural change in the heme
porphyrin ring structure, such as cleavage of the ring, and the
generation of an intermediate or complex without absorbance
characteristics. The compound 5a-cholestan-3b-ol-6-one caused a
moderate reduction in heme Soret band absorption along with the
generation of a new absorption peak(s) over-lapping the Soret
415 nm peak (right shoulder in Figure 7). The nature of the
chemical species underlying this additional peak is not known. The
compound 3-hydroxy-4(succin-2-yl)-caryolane d-lactone was the
least reactive compound and caused only a small reduction in
heme Soret band without evidence of new absorption peaks.
HI HTS compound cytotoxicity and dependence upon
heme synthesis
The cytotoxic effects of the 4 lead compounds on the
proliferation and viability of MOLT-4 cells was determined
(Figure 8). Cells were seeded and exposed to compounds at
40 uM in the medium for up to 48 hours, a higher drug
c o n c e n t r a t i o nt h a ni np r e v i o u se x p e r i m e n t sw a su s e di no r d e r
to detect cytotoxicity from weaker HI compounds. In this
experiment, at 48 hours, the ATP content [25] in the DMSO
control cells increased by over 200% relative to time=0, which
was normalized to 100% in Figure 8,w i t hA T Pl e v e lw i t hA L A
increasing by 140% and those exposed to ALA/SA increasing by
187%, both normalized to 100%. No impact on ATP levels was
seen from 3-hydroxy-4(succin-2-yl)-caryolane d-lactone. A small
reduction in cell viability was seen with exposure to 5a-cholestan-
3b-ol-6-one (an increase in ATP of 88%). Artemisinin had a
modest impact on cell viability (an increase in ATP of 67%), in
contrast to the strong effects seen with certain artemisinin
derivatives, such as DHA used in Figure 1, consistent with
previous reports of differential cytotoxicity among artemisinin
compounds [45,46]. DHA is the reduced lactol derivative of
artemisinin, and semi-synthetic derivatives such as artemether,
arteether, artesunate and artelinate are ethers or esters of the
lactol. Differential solubility and/or chemical reactivity with
heme may account for differences in cytotoxicity among these
derivatives. The strongest cytotoxic effect of the 4 HI compounds
was seen with coralyne (an increase in ATP of 33%), previously
been shown to be an anti-cancer agent whose mechanism has
been attributed to inhibition of topoisomerase I activity
[47,48,49].
The effect of increasing heme synthesis on the cytotoxicity of
HI HTS compounds was determined by co-incubation with
1 mM ALA. ALA had no effect upon of 5a-cholestan-3b-ol-6-one
or 3-hydroxy-4(succin-2-yl)-caryolane d-lactone. Co-incubation
of ALA with artemisinin, however, caused a great reduction in cell
viability, with a net 27% reduction in ATP content from the initial
culture at time=0. ALA also resulted in a dramatic reduction in
cell viability when co-incubated with coralyne, with a net loss in
ATP content of 19%. These results suggest that the mechanism of
cytotoxicity due to coralyne may be in part dependent upon
heme.
Inhibition of heme synthesis by SA was used to reverse the
effects of ALA. Incubation with SA/ALA had little effect upon
cell viability with 3-hydroxy-4(succin-2-yl)-caryolane d-lactone
Figure 7. Absorption spectra of HI compounds. Absorption
spectra of the four HI compounds were recorded over the wavelength
range of 400 nm to 500 nm, which includes the heme Soret band
absorption peak. The compound to heme molar ratio was 10:1
(200 uM:20 uM). Two of the four lead heme interacting compounds
caused a substantial reduction in A415.
doi:10.1371/journal.pone.0007472.g007
Figure 8. Heme synthesis modulates cytotoxicity of artemisinin
and coralyne in MOLT-4 cells. The cytotoxicity of two heme
interacting compounds can be modulated by increasing or decreasing
heme synthesis. MOLT-4 cells were cultured for 48 hrs with the
compounds shown, with or without ALA or ALA/SA.
doi:10.1371/journal.pone.0007472.g008
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one relative to incubation with ALA without SA. We conclude
that modulation of heme synthesis has little effects upon
cytotoxicity from these two compounds, consistent with their
much lower reactivity towards heme than either artemisinin or
coralyne.
In contrast, the presence of SA completely prevented the
increase in artemisinin’s toxicity from ALA and resulted in cell
viability similar to artemisinin alone. SA also prevented the
increased cytotoxic effects of coralyne by ALA and resulted in a
cell viability level even higher than the culture treated only with
coralyne. We conclude that modulation of heme synthesis has
significant effects upon cytotoxicity from artemisinin and
coralyne, consistent with their high reactivity towards heme in
vitro. These data further support heme as a molecular target for
cytotoxicity.
The HI HTS assay appears to distinguish among slight
differences in structure. The compound palmatine, also present
in the compound library and which shares high structural
similarity with coralyne (Figure 9), does not react with heme
and shows no toxicity towards Molt-4 cells (Figure 8). Berberin,
another close structural relative of coralyne present in the
compound library, also possesses cytotoxic activity [50,51] but
did not react in the HI HTS assay. Berberin at 40 uM exhibited
strong cytotoxicity against Molt-4 cells (Figure 9). In contrast to
coralyne, ALA appeared to be somewhat protective, while SA
slightly increased cytotoxicity (Figure 9). A major structural
difference that distinguishes coralyne from both palmatine and
berberin is the presence of a fully aromatic ring structure that is
disrupted in palmatine and berberin due to reduction in the
nitrogen-containing ring. Therefore a planar configuration and
broad dislocation of p-electrons in coralyne are not present in
palmatine and berberin, which may account for their inaccessi-
bility and/or chemical non-reactivity with heme. The interaction
of coralyne with heme may be due to the favorable planar ring
structure which may allow for physical association and a strong
stacking interaction.
Discussion
Artemisinins exhibit both anti-malarial activity and selective
cytotoxicity against cancer cells. We previously have shown that
heme is the kinetically favored iron species that can react with
artemisinin [3]. We show here that heme is also involved in the
mechanism of the cytotoxic effects of artemisinins in at least three
different cell lines, suggesting that this may be a generalizable
mechanism. Heme is an essential cellular molecule whose redox
properties and participation in a variety of important cellular
functions render it a potentially valuable molecular target for the
development of anti-neoplastic agents. The essential role of heme
in mediating the anti-malarial activity of artemisinin drugs, and
the dual effectiveness of the artemisinin compounds against
malaria parasites and cancer cells, is consistent with our findings
that heme plays a similar role in mediating cytotoxicity [9].
Cancer cells have been shown to be much more sensitive to
artemisinins than their normal counterparts [27,36], and cancer
cell lines with a low percentage of G0/G1 cells and a high
percentage of S-phase cells have been found to be most sensitive to
artemisinin drugs, consistent with the relatively increased rate of
heme synthesis needed for cell division [9]. Cancer cells also differ
significantly from normal cells in their heme synthetic capacity
[19], which is the basis for several types of photodynamic therapies
for cancer [21,22].
We used a simple assay to identify other heme interacting
compounds. The mechanism by which these compounds interact
with heme may vary. Heme is comprised of a coordination
complex formed between iron and the dianionic form of
porphyrin, a heterocyclic macrocycle derived from 4 pyrrole
subunits linked on opposite sides through 4 methine bridges. The
porphyrin ring is very hydrophobic and may promote interactions
with other hydrophobic molecules. Heme’s side chains may also
provide a means for interaction. Several forms of heme exist
depending upon the modification of side chains. The free form,
heme b, contains 4 methyl groups, two propionic side chains, and
two vinyl groups which can be modified for covalent linkage to
proteins.
Figure 9. Structures of lead heme interacting compounds and structurally related compounds.
doi:10.1371/journal.pone.0007472.g009
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contribute, iron moiety of heme plays a critical role. Heme iron is
coordinated to 4 pyrrole nitrogens within the pyrrole ring. The
fifth and sixth coordination positions can be liganded to proteins
or other molecules. Due to the coordinated iron, heme is a strong
reducing agent which may contribute to the interaction with HI
compounds, which could produce chemical disruption of heme’s
ring structure and loss of Soret band absorbance. The large
reduction of the Soret band A415 from coralyne, without the
appearance of any other spectroscopically detectable species, is
consistent with breakage of the heme ring structure, analogous to
the cleavage of DNA by coralyne [52]. The interaction of
artemisinins with heme appears to procede through several
intermediates as evidenced by new but unstable absorption peaks.
The initial new peak that occurs at 476 nm may be an
intermediate complex between heme and artemisinin radicals
[37], which is not stable and disappears [3], consistent with
decomposition of heme porphyrin ring.
Little is known about the molecular mechanisms responsible for
HI compound cytotoxicity. The mechanisms by which artemisi-
nins are selectively cytotoxic to cancer cells have been suggested to
include increasing reactive oxygen species and inhibiting hypoxia
inducible factor (HIF) alpha activation [53]. HIF is the primary
transcription factor that regulates gene expression in response to
hypoxia. During hypoxia, HIF-alpha levels accumulate and trigger
an increase in expression of genes involved in energy metabolism
and mitochondrial function, cell survival and apoptosis, and
resistance to oxidative stress [54], physiological processes that
require heme. HIF may also be involved in the inhibition of tumor
lymphangiogenesis by artemisinin through suppression of vascular
endothelial growth factor C [16]. Artemisinin has also been
reported to activate p38 mitogen-activated protein kinase (p38
MAPK) in human lung cancer cells [18]. HO-1, the primary
enzyme that metabolizes heme, can be significantly inhibited by
p38 MAPK inhibitors [55].
Coralyne and several of its structural analogues have been
shown to be inhibitors of DNA topoisomerase I, with structural
rigidity associated with the coralyne ring system thought to be
important for its pharmacological activity [47,48]. Palmatine and
berberin, which share significant structural similarity with
coralyne, are also DNA-binding alkaloids [50,51], although they
are not reactive with heme nor is their cytotoxicity affected by
heme synthesis as is coralyne. The binding of coralyne and
palmatine with nucleic acid in vitro may involve a substantial
hydrophobic interaction [50]. The identification of coralyne but
not its structural analogs as heme interacting compounds suggests
that its mechanism of cytotoxicity may be more complex.
The two most potent HI compounds, artemisinin and coralyne,
also both possess activity against parasites [56,57,58] and cancer
cells [49,59]. The dependence on heme synthetic activity for
cytotoxicity suggests a general mechanism for the pharmacological
function of these HI compounds in treating protozoan infections.
Analogous to cancer cells that exhibit high rates of proliferation,
malaria parasites at the intraerythrocytic stage replicate rapidly
and are highly susceptible to artemisinins through a mechansism
thought to involve heme derived from red blood cells [60].
However, malaria parasites produce heme by de nove synthesis
[61,62]. Our results suggest that artemisinins may interact with
parasite derived heme, which would explain why artemisinins can
effectively kill malaria parasites in host erythrocytes where the
hemoglobins are poisoned by carbon monoxide and the heme iron
is not available [63]. A similar mechanism may also exist for other
protozoan parasites, such as Leishmania, which are able to
synthesize heme from iron and protoporphyrin [64]. This is also
supported by the observation that the ferrous iron transporter of
Leishmania (LIT) is essential for parasite replication within
macrophages [65,66], suggesting that Leishmania parasites rely
on endogenous rather than exogenous heme that could interact
with the Leishmaniacides artemisinins [67,68,69] or coralyne
[56,57].
Supporting Information
Figure S1 Time course and dose response of DHA on Molt-4
cells. The proliferation of Molt-4 cells was significantly decreased
by concentrations of DHA exceeding 25 uM.
Found at: doi:10.1371/journal.pone.0007472.s001 (0.12 MB TIF)
Figure S2 Modulation of heme synthesis alters DHA cytotox-
icity in Molt-4 cells. Cell numbers were determined at the
beginning and the end of treatment, and the change during the
treatment was expressed as percentage, taking DMSO control as
100%. The data are presented as Mean6SD. (A) Cellular
proliferation of Molt-4 cells cultured with DHA, succinyl acetone
(SA), or both, for 24 hours was measured using cell number.
Values are mean +/2 s.d. for six replicates. SA resulted in a
statistically significant (p,0.05) increase in cell number. (B) Cell
numbers of Molt-4 cells cultured with DHA, aminolevulinic acid
(ALA), and/or SA. ALA further increased the cytotoxicity of DHA
(*p,0.05), which was reversed by SA.
Found at: doi:10.1371/journal.pone.0007472.s002 (1.50 MB TIF)
Figure S3 Effect of protoporphyrin IX and holotransferrin on
DHA cytotoxicity. (A) Cell numbers of Molt-4 cells cultured with
DHA, holotransferrin (HTF), and/or SA. HTF enhanced DHA
cytotoxicity (*p,0.05), which was reversed by SA. (B) Cell
proliferation of Molt-4 cells cultured with DHA, the heme
precursor protoporphyrin IX (PPIX) and/or SA. PPIX increased
DHA cytotoxicity (*p,0.05), which could not be reversed by SA,
consistent with PPIX acting later in the heme synthetic pathway
than SA.
Found at: doi:10.1371/journal.pone.0007472.s003 (1.50 MB TIF)
Figure S4 Reduction in absorbance at 415 nm in the presence
of various peroxides. Each peroxide compound was at 40 uM with
heme at 20 uM in dithionite sodium phosphate buffer solution
with 36% DMSO. Di-T-A= di-tert-amyl peroxide; tert-B= tert-
butyl peroxide; 2-But= 2-Butanone peroxide; Di-Cum= Dicu-
myl peroxide; Benz= Benzoyl peroxide; Laur= Lauroyl
peroxide; 5,8-Epi= 9-a,11-a-di-hydroxy-5,8-epidioxy-5-a,8-a-er-
gostan-3-b-yl acetate; DHA= Artesunate.
Found at: doi:10.1371/journal.pone.0007472.s004 (0.10 MB TIF)
Figure S5 Reaction between ferrous heme and artemisinins in
the presence of trolox (TLX) or BHT. Absorption spectra were
recorded over the wavelength range of 400 nm to 500 nm, which
shows that neither TLX nor BHT had any effect on the
interaction of heme and ART.
Found at: doi:10.1371/journal.pone.0007472.s005 (0.32 MB
DOC)
Figure S6 Day-to-day variation of the Heme Interaction assay.
Assays were conducted using an entire microplate for five
consecutive days. The ratio of artemisinin to hemin was 0.8:1.
Found at: doi:10.1371/journal.pone.0007472.s006 (0.13 MB TIF)
Figure S7 Secondary screen of the compounds selected from
primary screen. Compounds were used at 200 uM (10:1 molar
ratio to heme). Four compounds caused a 10% or more reduction
in A415 including artemisinin, coralyne, 5a-cholestan-3b-ol-6-one
and 3-hydroxy-4(succin-2-yl)-caryolane d-lactone.
Found at: doi:10.1371/journal.pone.0007472.s007 (0.09 MB TIF)
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Found at: doi:10.1371/journal.pone.0007472.s008 (0.03 MB
DOC)
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